Compare ITGR & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITGR | IRTC |
|---|---|---|
| Founded | 1970 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.7B |
| IPO Year | 2000 | 2016 |
| Metric | ITGR | IRTC |
|---|---|---|
| Price | $126.70 | $109.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 15 |
| Target Price | $121.80 | ★ $172.14 |
| AVG Volume (30 Days) | ★ 678.5K | 449.9K |
| Earning Date | 10-30-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.71 |
| EPS | ★ 1.17 | N/A |
| Revenue | ★ $1,853,637,000.00 | $747,138,000.00 |
| Revenue This Year | N/A | $19.40 |
| Revenue Next Year | $5.96 | $16.65 |
| P/E Ratio | $108.32 | ★ N/A |
| Revenue Growth | 7.98 | ★ 26.24 |
| 52 Week Low | $62.00 | $100.70 |
| 52 Week High | $126.80 | $210.01 |
| Indicator | ITGR | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 72.72 | 48.85 |
| Support Level | $126.16 | $107.33 |
| Resistance Level | $126.80 | $117.56 |
| Average True Range (ATR) | 0.13 | 3.63 |
| MACD | -0.21 | 0.44 |
| Stochastic Oscillator | 79.41 | 66.94 |
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns maximum of its revenue in the United States, and also has its presence in Ireland, Puerto Rico, Costa Rica, and Rest of the World.
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.